Divi’s Laboratories Faces ₹570 Crore Tax Demand
On March 21,2026 company disclosed that it received a draft tax assessment order proposing additions of ₹570.51 crore to its income for FY 2022–23.
On March 21,2026 company disclosed that it received a draft tax assessment order proposing additions of ₹570.51 crore to its income for FY 2022–23.
JB Pharma has been hit with a ₹80.81 lakh GST penalty, raising questions about tax compliance in the pharma industry. What led to this action, and should investors be concerned? Here’s a complete breakdown of the case and its implications.
Read MoreDr. Reddy’s Laboratories one of India’s leading pharmaceutical companies headquartered in Hyderabad, recently made headlines after disclosing GST demand orders totalling approximately ₹2.20 crore for the financial years FY20–22. Reported widely in March 2026, this development highlights the ongoing challenges companies face under India’s complex GST regime even those with strong compliance system.
Read More